Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Journey Medical (DERM) EPS (Weighted Average and Diluted) (2020 - 2025)

Journey Medical (DERM) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.09 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 18.18% year-over-year to -$0.09, compared with a TTM value of -$0.35 through Sep 2025, up 61.96%, and an annual FY2024 reading of -$0.72, down 242.86% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.09 for Q3 2025 at Journey Medical, up from -$0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.94 in Q3 2023 and bottomed at -$1.89 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.39, with a median of -$0.18 recorded in 2025.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 262.07% in 2023, while the deepest fall reached 612.5% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.89 in 2021, then soared by 68.25% to -$0.6 in 2022, then surged by 80.0% to -$0.12 in 2023, then surged by 166.67% to $0.08 in 2024, then tumbled by 212.5% to -$0.09 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for DERM at -$0.09 in Q3 2025, -$0.16 in Q2 2025, and -$0.18 in Q1 2025.